» Articles » PMID: 29949876

Phenotypic Variation During Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design

Overview
Publisher MDPI
Date 2018 Jun 29
PMID 29949876
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Various bacterial species cycle between growth phases and biofilm formation, of which the latter facilitates persistence in inhospitable environments. These phases can be generally characterized by one or more cellular phenotype(s), each with distinct virulence factor functionality. In addition, a variety of phenotypes can often be observed within the phases themselves, which can be dependent on host conditions or the presence of nutrient and oxygen gradients within the biofilm itself (i.e., microenvironments). Currently, most anti-biofilm strategies have targeted a single phenotype; this approach has driven effective, yet incomplete, protection due to the lack of consideration of gene expression dynamics throughout the bacteria’s pathogenesis. As such, this article provides an overview of the distinct phenotypes found within each biofilm development phase and demonstrates the unique anti-biofilm solutions each phase offers. However, we conclude that a combinatorial approach must be taken to provide complete protection against biofilm forming bacterial and their resulting diseases.

Citing Articles

-derived peptides disrupt quorum sensing and biofilm assembly in multidrug-resistant .

Leistikow K, May D, Suh W, Vargas Asensio G, Schaenzer A, Currie C mSystems. 2024; 9(8):e0071224.

PMID: 38990088 PMC: 11334493. DOI: 10.1128/msystems.00712-24.


Microbial Biofilms: Features of Formation and Potential for Use in Bioelectrochemical Devices.

Perchikov R, Cheliukanov M, Plekhanova Y, Tarasov S, Kharkova A, Butusov D Biosensors (Basel). 2024; 14(6).

PMID: 38920606 PMC: 11201457. DOI: 10.3390/bios14060302.


A review on mycogenic metallic nanoparticles and their potential role as antioxidant, antibiofilm and quorum quenching agents.

Cruz J, Muzammil S, Ashraf A, Ijaz M, Siddique M, Abbas R Heliyon. 2024; 10(8):e29500.

PMID: 38660254 PMC: 11040063. DOI: 10.1016/j.heliyon.2024.e29500.


Comparative analysis of biofilm characterization of probiotic .

Liu H, Ma J, Yang P, Geng F, Li X, Lu J Front Microbiol. 2024; 15:1365562.

PMID: 38559351 PMC: 10978722. DOI: 10.3389/fmicb.2024.1365562.


Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies.

Dsouza F, Dinesh S, Sharma S Arch Microbiol. 2024; 206(2):85.

PMID: 38300317 DOI: 10.1007/s00203-023-03802-7.


References
1.
Ghasemian A, Najar Peerayeh S, Bakhshi B, Mirzaee M . The Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) Genes among Clinical Isolates of Staphylococcus aureus from Hospitalized Children. Iran J Pathol. 2015; 10(4):258-64. PMC: 4539745. View

2.
Tchesnokova V, Aprikian P, Kisiela D, Gowey S, Korotkova N, Thomas W . Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli. Infect Immun. 2011; 79(10):3895-904. PMC: 3187269. DOI: 10.1128/IAI.05169-11. View

3.
van Gestel J, Vlamakis H, Kolter R . Division of Labor in Biofilms: the Ecology of Cell Differentiation. Microbiol Spectr. 2015; 3(2):MB-0002-2014. DOI: 10.1128/microbiolspec.MB-0002-2014. View

4.
Kaplan J . Therapeutic potential of biofilm-dispersing enzymes. Int J Artif Organs. 2009; 32(9):545-54. DOI: 10.1177/039139880903200903. View

5.
Kwan B, Chowdhury N, Wood T . Combatting bacterial infections by killing persister cells with mitomycin C. Environ Microbiol. 2015; 17(11):4406-14. DOI: 10.1111/1462-2920.12873. View